60 minutes
Despite massive investments in research for diseases like Alzheimer's and Parkinson's, treatment options for patients are largely non-existent. 'Soft' clinical endpoints like Cogntivie Impression scores are difficult to demonstrate statistical significance even when underlying biology is being modified. Industry and practicing clinicians share how they are introducing modern imaging and biomarker measurements as 'harder' endpoints to the FDA, along with including diverse patients in earlier trials to better predict large pivotal trials.


Gilmore O'Neill - Executive Vice President, R&D and Chief Medical Officer, Sarepta
John Torous, MD MBI - Director of Digital Psychiatry, Beth Israel Deaconess Medical Center
Joseph J. Higgins, MD FAAN - Vice President, Clinical Development, Huntington's Disease Program Lead, Uniqure
Robert Alexander - Vice President and Head, Clinical Science, Neuroscience Therapeutic Area Unit, Takeda
Sally John - VP Genomics and Computational Biology, Biogen
Steve Wood - Scientific Director, Neuroscience Department, Amgen
Name Audience
Science Track